“Patients from every part of the world need access to affordable medicines.” Globally, there has been heightened focus on health disparities and increased prioritization of health equity. In this podcast, Kiran Mazumdar-Shaw talks about how Biocon has deliberately steered clear of the inherent inequities of business models followed in wealthy Western countries wherein a new … Continue reading Transforming Healthcare: Kiran Mazumdar-Shaw’s Vision for Affordable Access and Compassionate Capitalism
Reinventing Supply Chains of Tomorrow
By Kiran Mazumdar-Shaw The aftermath of the COVID-19 pandemic and the ongoing Russia-Ukraine war have triggered massive disruptions in global supply chains, revealing the vulnerability of networks that were largely built on cost optimisation. Supply chains are critical to global growth, so their reinvention is vital to rebuilding economies in the post pandemic world. A … Continue reading Reinventing Supply Chains of Tomorrow
India’s Life Sciences Industry Poised for the Next Level
By Kiran Mazumdar-Shaw Over the last 20 years, life sciences in India has gone from being a nascent sector to a sunrise industry. When I began my own entrepreneurial journey in 1978, little did I know that I was sowing the seeds of the country’s biotechnology revolution. Up until the mid-1980s, I was the lone … Continue reading India’s Life Sciences Industry Poised for the Next Level
A game-changing, transformational deal that is an inflection point in Biocon Biologic’s journey of making global impact: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading A game-changing, transformational deal that is an inflection point in Biocon Biologic’s journey of making global impact: Kiran Mazumdar-Shaw
The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League
Budget: Taking Strides Towards Digital Health
By Kiran Mazumdar-Shaw It was very heartening to see a Budget empathize with those who had to bear adverse health effects of the pandemic. The wide coverage of our nation’s vaccination drive greatly helped amidst the 3rd wave of the pandemic caused by the Omicron variant, resulting in milder symptoms. Even though India is in … Continue reading Budget: Taking Strides Towards Digital Health
A Fair Budget that Balances the Needs of the Indian Economy
By Kiran Mazumdar-Shaw Finance Minister Nirmala Sitharaman has presented the nation with a balanced Budget for FY23. The Indian economy needs a steadying hand at a time when it is trying to find its feet as the tremors from the global COVID-19 pandemic recede slowly. She has prudently laid the groundwork for a gradual economic … Continue reading A Fair Budget that Balances the Needs of the Indian Economy
A Balanced Budget
By Kiran Mazumdar Shaw, Chairperson, Biocon Finance Minister Nirmala Sitharaman has delivered a Budget that ticks several boxes. The Budget focused on maintaining fiscal prudence, improving ease of doing business, boosting infrastructure, and creating a strong digital governance architecture. The economic gloom caused by the Covid-19 pandemic had raised expectations of a ‘feel good’ budget. … Continue reading A Balanced Budget
Budget Offers an Opportunity To Strengthen India’s R&D and Innovation Ecosystem
By Kiran Mazumdar-Shaw The Indian pharmaceutical industry has been playing a key role in improving global health through its affordable and high-quality generic medicines. We are the third largest pharmaceuticals supplier in terms of volume, supplying 60,000 generic brands across 60 therapeutic categories worldwide. India now needs to capture value share as well. To move … Continue reading Budget Offers an Opportunity To Strengthen India’s R&D and Innovation Ecosystem
$150-Billion Bioeconomy by 2025: Policy Prescriptions for Building a Vibrant Biotech Sector
By Kiran Mazumdar-Shaw In the face of the biggest health calamity faced by humanity in a century, India’s Bioeconomy grew over 12% to reach $70.2 billion in 2020. The biotech industry braved the challenges of Covid-19 to develop innovative solutions such as diagnostics, therapies and vaccines at speed and scale to save countless lives. India … Continue reading $150-Billion Bioeconomy by 2025: Policy Prescriptions for Building a Vibrant Biotech Sector